慢性粒细胞白血病研究进展  

Progress of chronic myeloid leukemia

作　　者：赵晨星 胡建达[1] Zhao Chenxing;Hu Jianda(Department of Hematology,Union Hospital Affiliated to Fujian Medical University,Fujian Provincial Key Laboratory of Hematology,Fujian Institute of Hematology,Fuzhou 350001,China)

机构地区：[1]福建医科大学附属协和医院血液科福建省血液病学重点实验室福建省血液病研究所,福州350001

出　　处：《白血病．淋巴瘤》2022年第3期133-136,共4页Journal of Leukemia & Lymphoma

摘　　要：在酪氨酸激酶抑制剂(TKI)治疗时代,慢性粒细胞白血病(CML)已具有“慢病化管理”的趋势。虽然四代TKI药物相继出现,但是CML的治疗需求仍有许多未被满足,无治疗缓解的实现及停药后复发仍是当前CML治疗关注的重点。文章对2021年第63届美国血液学会年会关于CML研究进展的报道作一介绍。In the tyrosine kinase inhibitor(TKI)therapy era,patients with chronic myeloid leukemia(CML)have embarked on the trend of"chronic disease management".With the advent of 4 generations TKI drugs,there remain unmet needs for optimal CML treatment,such as treatment-free remission and disease recurrence after discontinuation.This article reviews the research progress of CML at the 63rd American Society of Hematology annual meeting.

关 键 词：白血病 粒细胞 慢性 酪氨酸激酶抑制剂 停药试验 

分 类 号：R733.72[医药卫生—肿瘤]